RT Journal Article
SR Electronic
T1 A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.12.23288325
DO 10.1101/2023.04.12.23288325
A1 Bennett, Jennifer N.
A1 Blough, Michael D.
A1 Mitchell, Ian
A1 Galloway, Lyle
A1 Bains, Ravinder
YR 2023
UL http://medrxiv.org/content/early/2023/04/19/2023.04.12.23288325.abstract
AB This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin, are increasingly being recognized as a successful treatment option for many mental health concerns. In order to decrease the risks associated with its clinical use, more data is required regarding its physiological effects in healthy individuals. Safety assessments (heart rate, blood pressure, temperature, and ECG data), as well as adverse event evaluations were the primary outcome measures used to assess the physiological effects of 25 mg of psilocybin extract administered to 14 healthy individuals. We hypothesized that there would be a transient, clinically insignificant rise in both blood pressure and heart rate that would not result in any long-term adverse effects. No unexpected effects were observed, blood pressure and heart rate returned to normal as drug effects waned, and all participants had normal two-month follow-ups. Mean peak systolic and diastolic blood pressures during the psilocybin session were 145.93 (SD = 19.01) and 93.93 (SD = 9.75), respectively. While this represents a significant increase from baseline (p < 0.0001), a healthy cardiovascular system is capable of tolerating such levels for a longer time period than the brief duration of drug effects. Therefore, we suggest implementing focused and limited screening protocols to balance patient safety and accessibility. Secondary outcomes of this trial centered on the subjective effects of psilocybin, assessed via the QIDS-SR16 and the MEQ-30. There was a statistically significant decrease in QIDS-SR16 scores from baseline scores (M = 3.50, SD = 2.35) to eight-week follow-up scores (M = 1.86, SD = 0.86), p = 0.018. Mean MEQ-30 scores, assessed on day two and seven after the psilocybin session, indicate participants had full mystical experiences.Competing Interest StatementJennifer N. Bennett is a Medical Writer and Research Assistant at ATMA Journey Centers Inc. Michael D. Blough is the Chief Science Officer at ATMA Journey Centers Inc. Ravinder Bains is the Chief Medical Officer at ATMA Journey Centers Inc. Lyle Galloway is a Medical Advisor at ATMA Journey Centers Inc. Ian Mitchell is an instructor for the ATMA Journey Centers Inc. Introduction to Psychedelic-Assisted Therapy course.Clinical TrialISRCTN15259909Funding StatementThis study was funded by ATMA Journey Centers Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Health Research Ethics Board of Alberta, Clinical Trials Committee gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://doi.org/10.6084/m9.figshare.22329433.v1